The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the hard way, watching the same manufacturing process succeed brilliantly with one donor and fail completely with the next. In this episode, she explains why starting material variability is the defining challenge of cell therapy manufacturing, and what it actually takes to build a process robust enough to survive it.

Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. She holds a PhD in immunology and has spent two decades advancing T cell therapy from early research programs at MD Anderson to GMP-compliant clinical manufacturing. She holds four patents in adoptive cell therapy.

Key topics discussed:

• Personal journey: from immunology PhD in Quebec to cell therapy leadership in Houston (04:25)
• Evolution of TIL therapy at MD Anderson, including manufacturing innovations to overcome declining T cell yields (06:14)
• The fundamental differences between traditional medicines and cell-based immunotherapies (10:01)
• Unique manufacturing complexities for autologous therapies, including batch variability and process standardization (11:19)
• Strategies to address decreased cell fitness in heavily pretreated patients, including changes in cell activation and culture conditions (13:57)
• Key learnings from the CAR T and TIL manufacturing process: balancing process duration, cell fitness, and product yield (16:28)
• Mechanistic differences between CAR T and TIL therapies and their implications for efficacy and resistance (17:58)
• The limits and risks of automation in cell therapy manufacturing—balancing manual vs. automated processes (24:04)
• Why moving between manufacturing platforms raises challenges in comparability and clinical outcomes (25:44)
• The ongoing search for critical cell quality attributes that correlate with patient response (27:00)

In part two, Chantale goes deeper into next-generation approaches, technology transfer, and what needs to change to broadly expand patient access.

Smart insight: In cell therapy, manufacturing isn’t just a production step. It defines the therapy itself. Because each patient’s starting cells are unique, even subtle changes in the process can significantly alter clinical outcomes.

If you’re interested in exploring further the concepts we touched on—such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:

• Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
• Episodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
• Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver Kraemer

Connect with Chantale Bernatchez:

LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511

CTMC website: www.ctmc.com

Support the show

Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.

Ron Najafi knows what rigorous analytical work actually looks like under pressure. As founder and CEO of Emery Pharma, he led the investigation that identified NDMA as a degradation product of ranitidine — findings the FDA formally validated and that reshaped how the industry approaches nitrosamine risk assessment. In Part 2, he moves from that scientific foundation into the operational questions that determine whether a CRO partnership accelerates your program or quietly slows it down.

If you haven't heard Part 1, it covers Ron's career arc and the technical details of nitrosamine contamination in pharmaceutical development. This episode stands on its own for anyone focused on CRO selection, bioanalytical strategy, and what three decades of building analytical companies actually teaches you.

Topics discussed:

• How to tell if a CRO’s workflow is robust—or just rigid (05:51)
• The importance of method validation and product stability testing (07:27)
• Managing expectations and trust-building in client relationships (08:29)
• Entrepreneurial lessons: raising capital, team-building, and finding the right partners (10:00)
• The hidden costs of public vs. private biotech ventures (12:31)
• Reducing bioanalytical costs in biologics through mass spectrometry (13:23)
• The future of analytical workflows and personalized medicine (14:48)

Smart insight:

In biotech, success isn’t just about the science—it’s about strategic discipline. Ron emphasizes a few hard-earned principles: raise more capital than you think you’ll need, don’t fixate on valuation, and invest in smart, creative talent. Just as important, real value is unlocked through strong partnerships and the ability to manage collaborations and acquisitions with intention.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

• Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 139 - 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Support the show

When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.

Ron Najafi has lived that reality firsthand. As founder of NovaBay Pharmaceuticals and Emery Pharma, he spent decades building companies at the intersection of analytical chemistry and drug development. His investigation into nitrosamine contamination in ranitidine — which led the FDA to formally validate Emery Pharma's findings — remains one of the most consequential episodes in recent pharmaceutical quality history.

In Part 1, Ron traces the scientific and entrepreneurial path that led him there, and shares what CMC teams working in drug development need to understand about impurity risk before it becomes a regulatory crisis.

Episode highlights:

• Early academic experiences and inspirations that Ron Najafi to a science career (05:46)
• Challenges and milestones in building companies like CP Lab Safety and NovaBay Pharmaceuticals (07:59)
• The invention and impact of the ECO Funnel® on lab safety and environmental responsibility (12:01)
• The formation of Emery Pharma following industry setbacks and lessons in adaptation (17:03)
• The fundamentals of impurity risk analysis, especially nitrosamine contamination in pharmaceuticals (20:56)
• The ranitidine (Zantac) NDMA discovery, its investigation, and consequences for drug regulation (23:33)
• Common sources of nitrosamine and practical advice for bioprocess risk management (27:51)
• Differences in impurity risk between small molecule and biologic drug processes (28:03)
• The necessity and regulatory expectation of impurity and leachable/extractable analysis (30:07)

Smart insight:

One of Ron's clients conducted a superficial nitrosamine risk assessment, proceeded to manufacturing, and spent approximately $6 million producing three batches. At final FDA-required testing, NDMA came back at 11,000 nanograms per pill against an acceptable daily intake limit of 96 nanograms. The batches were unusable.

A thorough risk assessment run earlier would have cost a fraction of that. If you are developing a drug with secondary or tertiary amines in your process and have not yet conducted a formal nitrosamine risk assessment, that is the one action to take after listening to this episode.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

• Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Support the show

Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a key enabler your CMC development is missing.

Tibor Anderlei, CSO at Kühner Shaker, joined David Brühlmann on the Smart Biotech Scientist Podcast to unpack the hidden physics behind bioprocess reproducibility and next-generation shaking technology. He has seen firsthand how overlooking fundamental parameters can derail scale-up and delay development timelines. In his role, Tibor is responsible for the customer interface—spanning sales, service, support, GMP topics, troubleshooting, marketing, and applied technology—with a focus on orbital shaking technology and small-scale cultivation support.

Topics discussed:

• The importance of measuring oxygen transfer rate (OTR) and carbon dioxide transfer rate (CTR) for reproducible bioprocesses—why DO is not sufficient (02:55)
• Real-time process analytical technology (PAT) for small-scale bioreactors, including microtiter plates and shake flasks (06:47)
• Pre-culture reproducibility: transferring at the right OTR and its impact on main cultures (07:56)
• Price sensitivity and scale-up challenges in cultivated meat—implications for media and equipment selection (10:36)
• Expansion of shaking technology to fields such as mixing, storage, and thawing, including applications in liquid crystal production (12:10)
• Leadership lessons from competing with bigger players: how smaller companies stay innovative, agile, and close to their customers (14:20)
• The significance of strong business partner relationships and trusting gut feeling in decision-making (16:32)
• Key advice for smart biotech scientists: careful definition of screening conditions and the use of online measurement tools at small scale (18:09)
• Accessible resources for mastering shaken bioreactor techniques, including webinars and direct contact with Tibor Anderlei (19:38)

Smart insight:

Treat small-scale shaken systems as real bioreactors and define screening conditions carefully from the start. Using online measurement tools even at early stages provides critical visibility and helps ensure that results are reproducible and scalable.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

• Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
• Episode 25 - 26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
• Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
• Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?

Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.

Topics discussed:

• Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)
• The gap between educational practices and real-world bioreactor expertise (04:00)
• Tibor Anderlei’s journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)
• Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)
• Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)
• Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)
• Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)
• The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)

Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.

Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

• Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
• Episode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
• Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
• Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

When a single mismanaged tech transfer threatens an entire development program, pressure on CMC leaders and bioprocess teams is intense. The truth? Tech transfers aren’t a black box. They’re complex, but solvable with the right mindset and playbook.

In this episode, David Brühlmann explores the practical side of tech transfer and scale-up within the biotech industry. With more than 15 years of experience, he shares personal stories and industry-tested frameworks that help demystify the complexities of transferring technologies between sites or organizations. Instead of focusing solely on technical details, he emphasizes the crucial human and organizational factors that often decide project success or failure.

Key topics discussed:

• How mapping and managing stakeholders can resolve hidden issues and accelerate projects (01:55)
• Case studies highlighting the importance of environmental factors — like light exposure — in process performance and troubleshooting (05:50)
• A mass transfer checklist for bioprocess scale-up, with specific focus on equipment-related parameters (07:09)
• The build vs. outsource dilemma: how to choose what to keep in-house and what to partner out, depending on company strategy and project phase (08:05)
• A 12-week tech transfer preparation protocol, covering foundations, risk mitigation, and execution readiness (10:16)
• Lessons on leadership, prioritization, and effective delegation to avoid personal and organizational bottlenecks (13:28)

Whether you're overseeing a complex CMC program, navigating CDMO relationships, or planning your next scale-up, this episode offers concrete steps to cut through confusion and deliver results.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

• Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
• Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

What if the hidden cost of your bioprocess lies not in the technology, but in what you don’t document?

Too often, biotech teams discover too late that their “proven” process is just an illusion, propped up by undocumented tricks and missing critical parameters. In this episode, David Brühlmann strips down the assumptions behind scale-up and tech transfer, exposing the silent risks that threaten CMC milestones and market launches alike. After 15 years guiding biotech projects from bench to clinic, he’s felt the pain of process gaps, regulatory curveballs, and million-dollar mistakes. Here, he turns that experience into a tactical guide designed to save you from the same pitfalls.

In this episode, you’ll learn about:

• The 6-pillar approach to turning tech transfer into a managed process, rather than a gamble (03:09)
• Why mass transfer physics and factors like kLA are critical—and how they can make or break a process at scale (05:12)
• The importance of analytical comparability, including the common blind spots in sampling plans and method validation (07:19)
• Establishing a solid Quality by Design (QbD) foundation and defining critical quality attributes before transfer, not after failures (08:33)
• Stakeholder management and why non-technical challenges often derail projects (with more on this in Part 2) (10:09)
• Evaluating CDMO partners: What selection criteria really matter for long-term success and risk mitigation (11:03)
• Strategic decision-making: Building core capabilities versus outsourcing, and how to avoid unnecessary costs and delays (12:22)

This episode sets the stage for Part 2, where David Brühlmann will share practical stories and detailed frameworks for real-world implementation. If you manage bioprocess scale-up, tech transfer, or CMC development, you’ll find plenty of actionable insights to apply in your own work.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

• Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
• Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?

This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from the bench to the clinic.

Episode highlights:

• Biological insights from Arctic fish and their translation into synthetic peptide chemistry for cell preservation (00:23)
• The effect of ice crystal formation on cellular damage, and how XT Thrive® minimizes this compared to DMSO (05:32)
• Simplified logistics: reduced risk of contamination, elimination of post-thaw wash steps, and implications for therapy delivery to remote locations (07:23)
• Applicability beyond single cells—preserving organoids and potential implications for tissue engineering (09:50)
• The ease of transitioning from DMSO to the new solution in established lab protocols (10:49)
• Broader industry challenges: maintaining purity, process optimization, and reducing cost of goods in cell therapy manufacturing (12:03)
• Promising innovations in rapid cell type differentiation and barriers to scaling transformative biotech (12:50)
• The importance of supporting innovative therapies beyond short-term ROI (14:17)

Smart insight:

Next-generation cryopreservation solutions address more than just viability—they simplify transport, reduce costs, lower hands-on time, and help ensure therapy reaches patients in remote locations in optimal condition. As Steve Oh observes, these advances are critical for reducing the cost of goods, improving consistency, and enabling truly scalable cell therapy manufacturing.

If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation—transforming how life-saving cells are frozen, stored, and shipped.

• Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen

This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.

• Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.

Connect with Steve Oh:

Email: skwohso@gmail.com

LinkedIn: www.linkedin.com/in/steve-oh-4946261/

Support the show